Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 12 500 UNITS IN SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Head-to-head clinical analysis: HEPARIN SODIUM 12 500 UNITS IN SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III (ATIII), accelerating its inhibition of thrombin (factor IIa) and factor Xa, thereby preventing fibrin clot formation.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Intravenous: Initial bolus of 5,000 units followed by continuous infusion of 13-21 units/kg/hour (typically 1,000-2,000 units/hour) titrated to aPTT 1.5-2.5 times control. Subcutaneous: 5,000 units every 8-12 hours for prophylaxis; 10,000-20,000 units every 12 hours for treatment.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (dose-dependent, saturable clearance); prolonged to 2-6 hours in renal impairment, obese patients, or with high doses; clinical anticoagulant effect may persist 2-4 hours after a single IV bolus.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Primarily renal (via reticuloendothelial system); 40-50% excreted unchanged in urine; 20-30% metabolized to uroheparin and excreted renally; minor biliary (<5%).
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte